SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,020.98 |
| Enterprise Value ($M) | 898.79 |
| Book Value ($M) | 72.39 |
| Book Value / Share | 0.63 |
| Price / Book | 14.10 |
| NCAV ($M) | 72.19 |
| NCAV / Share | 0.63 |
| Price / NCAV | 14.14 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.22 |
| Return on Assets (ROA) | -3.56 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.30 |
| Current Ratio | 2.30 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 127.57 |
| Assets | 127.78 |
| Liabilities | 55.39 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Shendelman Shoshana | 6.60 | -9.76 | |
| 13G | Janus Henderson Group Plc | 6.10 | ||
| 13G/A | Propel Bio Management, LLC | 10.50 | 69.66 | |
| 13G/A | Alyeska Investment Group, L.P. | 9.99 | 60.57 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.99 | 35.88 | |
| 13G/A | Orbimed Advisors Llc | 0.00 | -100.00 | |
| 13G/A | Armistice Capital, Llc | 0.00 | -100.00 | |
| 13G/A | Alexandria Real Estate Equities, Inc. | 15.40 | -4.28 | |
| 13G/A | Perceptive Advisors Llc | 5.90 | 0.00 | |
| 13G | Vestal Point Capital, LP | 5.40 | ||
| 13G/A | Fmr Llc | 3.14 | -18.33 | |
| 13G/A | Franklin Resources Inc | 9.99 | -0.98 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 309,538 | 1,428,074 | 21.68 | |
| 351,509 | 1,684,084 | 20.87 | |
| 309,322 | 1,197,424 | 25.83 | |
| 261,143 | 1,079,916 | 24.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALT – Altimmune, Inc. | ANIP – ANI Pharmaceuticals, Inc. |
| APGE – Apogee Therapeutics, Inc. | AQST – Aquestive Therapeutics, Inc. |
| ARCT – Arcturus Therapeutics Holdings Inc. |
Financial data and stock pages provided by
Fintel.io